益生菌补充治疗银屑病关节炎的疗效与安全性:一项随机对照试验
这项单中心随机双盲安慰剂对照试验纳入66例中度疾病活动的PsA患者,评估多菌种益生菌12周疗效。主要结局为第12周达到低疾病活动度或缓解(PASDAS≤3.2)且无治疗改变,益生菌组43% vs 安慰剂组65%(P=0.167),OR 0.4(95%CI 0.13-1.18)。益生菌未优于安慰剂,未改变肠道菌群或通透性。
要点
- 益生菌组与安慰剂组主要结局无统计学差异(43% vs 65%,P=0.167)。
- 益生菌未显著改善肠道通透性标志物、免疫细胞谱或粪便菌群组成。
- 未报告与研究产品相关的严重不良事件。
核心结论
- 在中度疾病活动的PsA患者中,多菌种益生菌补充12周未在达到治疗反应方面优于安慰剂。
- 益生菌未改变肠道菌群组成或肠道通透性标志物。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照试验(RCT),66例中度疾病活动(PASDAS>3.2至<5.4)的PsA患者按1:1随机接受多菌种(乳杆菌、双歧杆菌)益生菌或安慰剂12周。
主要发现
- 益生菌组13例(43%)和安慰剂组17例(65%)达到主要结局(P=0.167),对应OR为0.4(95%CI 0.13-1.18)。
- 患者报告的疼痛和总体评估是随时间改善的主要PASDAS组分,组间无差异。
- 第12周时两组在次要临床结局、肠道通透性标志物(连蛋白、钙卫蛋白、α1-抗胰蛋白酶)、免疫细胞谱或粪便菌群组成方面均无差异。
- 未报告与研究产品相关的严重不良事件。
关键数值与推荐
- 主要结局定义为第12周达到低疾病活动度或缓解(PASDAS≤3.2)且无治疗改变。
- 纳入标准为中度疾病活动(PASDAS>3.2至<5.4)且接受稳定免疫调节治疗的PsA患者。
临床怎么用
- 对于中度疾病活动的PsA患者,不推荐常规补充多菌种益生菌以改善疾病活动度。
- 益生菌补充未显示对肠道菌群或通透性有益,不支持其作为改善肠道屏障的干预手段。
局限性
- 主要分析仅纳入主要结局完整病例,未完全遵循意向性分析原则。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the clinical efficacy and safety of a multispecies probiotic in patients with PsA in moderate disease activity. METHODS: In this single-centre, randomized, double-blind, placebo-controlled trial (RCT), 66 PsA patients with moderate disease activity (Psoriatic Arthritis Disease Activity Score [PASDAS] > 3.2 to <5.4) on stable immunomodulatory therapy were randomized 1:1 to receive either a multispecies (Lactobacillus, Bifidobacterium) probiotic or placebo for 12 weeks. The primary outcome was treatment response at week 12, defined as achieving low disease activity or remission (PASDAS ≤3.2) without treatment change. Secondary outcomes included gut permeability markers, immune cell and microbiome composition. Analyses were conducted per a modified intention-to-treat (only complete cases for primary outcome), with sensitivity analyses using multiple imputation, per-protocol datasets and qPCR-based detection of the probiotic strains in stool (adherence). RESULTS: Fifty-six participants were included in the main analysis. Thirteen (43%) participants in the probiotic group and 17 (65%) in the placebo group achieved the primary outcome (P = 0.167). The corresponding odds ratio was 0.4 (95% CI 0.13-1.18). Patient-reported pain and global assessment were the main PASDAS components improving over time, with no between-group differences. No differences were observed in secondary clinical outcomes, gut permeability markers (zonulin, calprotectin, alpha-1-antitrypsin), immune cell profiles or stool microbiome composition between the groups at week 12. No serious adverse events related to the study product were reported. CONCLUSION: In this first RCT investigating probiotic supplementation in PsA, probiotic treatment did not show superiority over placebo in achieving treatment response, or altering gut microbiome, or permeability.
引用
- Bosch P, Lackner A, Dreo B, et al. Efficacy and safety of probiotic supplementation in PsA-a randomized controlled trial. Rheumatology (Oxford). 2026. PMID: 42832303. doi:10.1093/rheumatology/keag547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。